![Peter Davies](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Davies
Direttore/Membro del Consiglio presso
Bionomics Ltd.
Patrimonio netto: 24 596 $ in data 30/09/2026
Profilo
Mr. Peter M.
Davies is an Independent Non-Executive Director at Neuphoria Therapeutics, Inc., an Independent Non-Executive Director at Bionomics Ltd. and a Chief Business Officer at Leaf4life, Inc. He is on the Board of Directors at Neuphoria Therapeutics, Inc. and Bionomics Ltd. Mr. Davies was previously employed as a Managing Director by Apeiron Investment Group Ltd. He received his graduate degree from The University of Edinburgh.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
0,13% | 17/09/2026 | 6.909 ( 0,13% ) | 24 596 $ | 30/09/2026 |
Posizioni attive di Peter Davies
| Società | Posizione | Inizio |
|---|---|---|
Bionomics Ltd.
 Bionomics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and diseases of the central nervous system | Direttore/Membro del Consiglio | 01/07/2021 |
Leaf4life, Inc.
 Leaf4life, Inc. Miscellaneous Commercial ServicesCommercial Services LEAF4Life specializes in developing medicines targeting hypoxia-related disorders. The private company is based in Woburn, MA. The company's lead product, LEAF-4L6715, is a proprietary liposomal formulation of transcrocetin aimed at enhancing oxygen diffusion in patients with conditions such as acute respiratory distress syndrome (ARDS), cancer, and cardiovascular diseases. | Corporate Officer/Principal | - |
Precedenti posizioni note di Peter Davies
| Società | Posizione | Fine |
|---|---|---|
Apeiron Investment Group Ltd.
 Apeiron Investment Group Ltd. Investment ManagersFinance Apeiron Investment Group invests in both public and private companies located across the globe primarily in the United States. The firm targets companies operating across a broad range of sectors and industries. It participates in pre-seed, seed, early, later and growth stage transactions. The firm invests in funds. It also acquires minority interest. | Investitore di Private Equity | 01/01/2022 |
Formazione di Peter Davies
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
18
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and diseases of the central nervous system | Health Technology |
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apeiron Investment Group Ltd.
Apeiron Investment Group Ltd. Investment ManagersFinance Apeiron Investment Group invests in both public and private companies located across the globe primarily in the United States. The firm targets companies operating across a broad range of sectors and industries. It participates in pre-seed, seed, early, later and growth stage transactions. The firm invests in funds. It also acquires minority interest. | Finance |
Leaf4life, Inc.
Leaf4life, Inc. Miscellaneous Commercial ServicesCommercial Services LEAF4Life specializes in developing medicines targeting hypoxia-related disorders. The private company is based in Woburn, MA. The company's lead product, LEAF-4L6715, is a proprietary liposomal formulation of transcrocetin aimed at enhancing oxygen diffusion in patients with conditions such as acute respiratory distress syndrome (ARDS), cancer, and cardiovascular diseases. | Commercial Services |
